Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)

The summary for the Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional): The purpose of this Funding Opportunity Announcement (FOA) is to solicit competitive revision (formerly known as competitive supplement) applications from awardees with active Clinical and Translational Science Award (CTSA) Program hub awards (UL1) to support the demonstration, and/or dissemination, and/or implementation of highly innovative and impactful translational science projects that address the goals of the CTSA Program and are beyond the original scope of the approved parent project.
Federal Grant Title: Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-19-337
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.350
CFDA Descriptions: Information not provided
Current Application Deadline: September 27th, 2021
Original Application Deadline: September 27th, 2021
Posted Date: August 7th, 2019
Creation Date: August 7th, 2019
Archive Date: November 2nd, 2021
Total Program Funding:
Maximum Federal Grant Award: $750,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: August 7th, 2019
Applicants Eligible for this Grant
Public and State controlled institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See FOA for full eligibility details.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-19-337.html
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Drug Development Collaboratory (UG3/UH3 Clinical Trial Required)
Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Dis...
Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Dis...
Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortenin...
Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-...
Limited Competition: Revision Applications to Advance Evidence-Based Research Related to P...
A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for...
Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for E...
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2020 FederalGrants.com